78 related articles for article (PubMed ID: 19815812)
1. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
Meis S; Hamacher A; Hongwiset D; Marzian C; Wiese M; Eckstein N; Royer HD; Communi D; Boeynaems JM; Hausmann R; Schmalzing G; Kassack MU
J Pharmacol Exp Ther; 2010 Jan; 332(1):238-47. PubMed ID: 19815812
[TBL] [Abstract][Full Text] [Related]
2. Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats.
Barragán-Iglesias P; Mendoza-Garcés L; Pineda-Farias JB; Solano-Olivares V; Rodríguez-Silverio J; Flores-Murrieta FJ; Granados-Soto V; Rocha-González HI
Pharmacol Biochem Behav; 2015 Jan; 128():23-32. PubMed ID: 25449358
[TBL] [Abstract][Full Text] [Related]
3. Alanine-(87)-threonine polymorphism impairs signaling and internalization of the human P2Y11 receptor, when co-expressed with the P2Y1 receptor.
Haas M; Shaaban A; Reiser G
J Neurochem; 2014 May; 129(4):602-13. PubMed ID: 24524250
[TBL] [Abstract][Full Text] [Related]
4. P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death.
Xiao Z; Yang M; Lv Q; Wang W; Deng M; Liu X; He Q; Chen X; Chen M; Fang L; Xie X; Hu J
J Cell Biochem; 2011 Sep; 112(9):2257-65. PubMed ID: 21503959
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between purinergic receptor P2Y
Klaver D; Gander H; Frena B; Amato M; Thurnher M
Cell Mol Life Sci; 2024 Mar; 81(1):132. PubMed ID: 38472446
[TBL] [Abstract][Full Text] [Related]
6. Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure.
Qian K; Tang J; Ling YJ; Zhou M; Yan XX; Xie Y; Zhu LJ; Nirmala K; Sun KY; Qin ZH; Sheng R
EBioMedicine; 2023 Dec; 98():104863. PubMed ID: 37950995
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.
Kiaie SH; Hatami Z; Nasr MS; Pazooki P; Hemmati S; Baradaran B; Valizadeh H
Purinergic Signal; 2023 Oct; ():. PubMed ID: 37843749
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of P2Y receptor subtypes - an update.
von Kügelgen I
Purinergic Signal; 2024 Apr; 20(2):99-108. PubMed ID: 37697211
[TBL] [Abstract][Full Text] [Related]
9. P2Y
Klaver D; Thurnher M
Purinergic Signal; 2023 Sep; 19(3):501-511. PubMed ID: 37016172
[TBL] [Abstract][Full Text] [Related]
10. New paradigms in purinergic receptor ligand discovery.
Jacobson KA; Pradhan B; Wen Z; Pramanik A
Neuropharmacology; 2023 Jun; 230():109503. PubMed ID: 36921890
[TBL] [Abstract][Full Text] [Related]
11. The P2Y
Klaver D; Gander H; Dobler G; Rahm A; Thurnher M
Cell Mol Life Sci; 2022 Sep; 79(10):519. PubMed ID: 36107259
[TBL] [Abstract][Full Text] [Related]
12. Oscillatory calcium release and sustained store-operated oscillatory calcium signaling prevents differentiation of human oligodendrocyte progenitor cells.
Seidman RA; Khattab H; Polanco JJ; Broome JE; Sim FJ
Sci Rep; 2022 Apr; 12(1):6160. PubMed ID: 35418597
[TBL] [Abstract][Full Text] [Related]
13. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
14. Recommended tool compounds and drugs for blocking P2X and P2Y receptors.
Müller CE; Namasivayam V
Purinergic Signal; 2021 Dec; 17(4):633-648. PubMed ID: 34476721
[TBL] [Abstract][Full Text] [Related]
15. Control of Macrophage Inflammation by P2Y Purinergic Receptors.
Klaver D; Thurnher M
Cells; 2021 May; 10(5):. PubMed ID: 34064383
[TBL] [Abstract][Full Text] [Related]
16. That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes.
Kennedy C
Purinergic Signal; 2021 Mar; 17(1):9-23. PubMed ID: 33527235
[TBL] [Abstract][Full Text] [Related]
17. P2Y11 Agonism Prevents Hypoxia/Reoxygenation- and Angiotensin II-Induced Vascular Dysfunction and Intimal Hyperplasia Development.
Piollet M; Sturza A; Chadet S; Gabillard-Lefort C; Benoist L; Muntean DM; Aburel OM; Angoulvant D; Ivanes F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467058
[TBL] [Abstract][Full Text] [Related]
18. The human G protein-coupled ATP receptor P2Y
Gruenbacher G; Gander H; Dobler G; Rahm A; Klaver D; Thurnher M
Br J Pharmacol; 2021 Apr; 178(7):1541-1555. PubMed ID: 33463722
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Jacobson KA; IJzerman AP; Müller CE
Biochem Pharmacol; 2021 May; 187():114311. PubMed ID: 33130128
[TBL] [Abstract][Full Text] [Related]
20. AKAP5 complex facilitates purinergic modulation of vascular L-type Ca
Prada MP; Syed AU; Reddy GR; Martín-Aragón Baudel M; Flores-Tamez VA; Sasse KC; Ward SM; Sirish P; Chiamvimonvat N; Bartels P; Dickson EJ; Hell JW; Scott JD; Santana LF; Xiang YK; Navedo MF; Nieves-Cintrón M
Nat Commun; 2020 Oct; 11(1):5303. PubMed ID: 33082339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
